Supplemental Material for: Complete Response to Low-Dose Fam-Trastuzumab Deruxtecan in Recurrent Endometrial Cancer with Liver and Peritoneal Metastases: A Case Report
Year: 2026
Type: supplementary-materials
Abstract: Introduction: While fam-trastuzumab deruxtecan (T-DXd) has demonstrated significant efficacy in HER2-expressing solid tumors, its optimal dosing and tolerability in elderly or frail patients remain poorly defined. Evidence supporting upfront dose de-escalation in gynecologic malignancies is limited. Case Presentation: We report a 73-year-old frail woman with recurrent, metastatic endometrial carcinoma featuring hepatic and peritoneal metastases, HER2 immunohistochemistry 3+, and high-level ERBB2 amplification. Following progression on multiple platinum-taxane regimens, bevacizumab, surgery, hormonal therapy, and radiotherapy, the patient was treated with a fixed, reduced dose of T-DXd at 100 mg every 2 weeks (2.27 mg/kg per administration, approximately 63% of the standard dose intensity). She achieved a complete radiological response by 6 months, with clinical improvement and no remarkable adverse events, sustaining a progression-free survival exceeding 16 months at last follow-up. Conclusion: This case illustrates a favorable response to dose-reduced T-DXd in a frail patient with strongly HER2-driven endometrial cancer, raising the possibility of individualized dosing strategies that warrant evaluation in larger prospective or retrospective cohorts.
Source: Figshare
Institution: Karger Publishers (Switzerland)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7204589019